Synovial Fibroblast 1: Secretion response of primary human synovial fibroblast samples from one healthy and one rheumatoid arthritis donor to a panel of 10 stimuli and 10 small molecule inhibitors - Dataset (ID:20233)
- Detail
- Small Molecules Studied
- Primary Cells Studied
- Proteins Studied
- Unclassified Perturbagens Studied
- Data Columns
- Results
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | Protein Stimulus | Other Stimulus | Stimulus Concentration | Stimulus Conc Unit | ExpPlate | Measured Protein | Measured Protein MFI (a.u.) | Bead Count |
---|---|---|---|---|---|---|---|---|---|---|---|
N2586 | Lestaurtinib | 0.3 | uM | IL-17A | 100 | ng/mL | 3 | GM-CSF | 135.0 | 71 | |
N2586 | Ruxolitinib | 0.3 | uM | IL-17A | 100 | ng/mL | 3 | GM-CSF | 209.0 | 62 | |
N2586 | Tofacitinib | 0.3 | uM | IL-17A | 100 | ng/mL | 3 | GM-CSF | 206.0 | 59 | |
N2586 | IKK16 | 2.0 | uM | IL-17A | 100 | ng/mL | 3 | GM-CSF | 171.0 | 60 | |
RA2159 | IL-6 | 100 | ug/mL | 3 | GM-CSF | 206.0 | 70 | ||||
RA2159 | PD184352 | 0.1 | uM | IL-6 | 100 | ug/mL | 3 | GM-CSF | 210.0 | 56 | |
RA2159 | Lestaurtinib | 0.3 | uM | IL-6 | 100 | ug/mL | 3 | GM-CSF | 215.5 | 46 | |
RA2159 | Ruxolitinib | 0.3 | uM | IL-6 | 100 | ug/mL | 3 | GM-CSF | 196.5 | 60 | |
RA2159 | Tofacitinib | 0.3 | uM | IL-6 | 100 | ug/mL | 3 | GM-CSF | 200.5 | 62 | |
RA2159 | IKK16 | 2.0 | uM | IL-6 | 100 | ug/mL | 3 | GM-CSF | 203.0 | 58 | |
RA2159 | Sigma A6730 | 3.0 | uM | 3 | GM-CSF | 183.0 | 74 | ||||
N2586 | IL-6 | 100 | ug/mL | 3 | GM-CSF | 200.5 | 74 | ||||
N2586 | PD184352 | 0.1 | uM | IL-6 | 100 | ug/mL | 3 | GM-CSF | 193.0 | 74 | |
N2586 | Lestaurtinib | 0.3 | uM | IL-6 | 100 | ug/mL | 3 | GM-CSF | 182.0 | 65 | |
N2586 | Ruxolitinib | 0.3 | uM | IL-6 | 100 | ug/mL | 3 | GM-CSF | 181.0 | 77 | |
N2586 | Tofacitinib | 0.3 | uM | IL-6 | 100 | ug/mL | 3 | GM-CSF | 198.0 | 67 | |
N2586 | IKK16 | 2.0 | uM | IL-6 | 100 | ug/mL | 3 | GM-CSF | 216.0 | 74 | |
N2586 | Sigma A6730 | 3.0 | uM | 3 | GM-CSF | 167.0 | 60 | ||||
RA2159 | IL-1 alpha | 100 | ng/mL | 3 | GM-CSF | 254.0 | 58 | ||||
RA2159 | PD184352 | 0.1 | uM | IL-1 alpha | 100 | ng/mL | 3 | GM-CSF | 264.0 | 61 | |
RA2159 | Lestaurtinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 3 | GM-CSF | 206.0 | 63 | |
RA2159 | Ruxolitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 3 | GM-CSF | 249.0 | 75 | |
RA2159 | Tofacitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 3 | GM-CSF | 225.0 | 60 | |
RA2159 | IKK16 | 2.0 | uM | IL-1 alpha | 100 | ng/mL | 3 | GM-CSF | 190.0 | 42 | |
RA2159 | PI103 | 0.1 | uM | 3 | GM-CSF | 214.0 | 43 |